Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-α Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence

The Journal of Rheumatology
Bunyamin KisacikAhmet Gul

Abstract

Screening strategies for latent tuberculosis (TB) before starting tumor necrosis factor (TNF)-α inhibitors have decreased the prevalence of TB among patients who are treated with these agents. However, despite vigilant screening, TB continues to be an important problem, especially in parts of the world with a high background TB prevalence. The aim of this study was to determine the factors related to TB among a large multicenter cohort of patients who were treated with anti-TNF. Fifteen rheumatology centers participated in this study. Among the 10,434 patients who were treated with anti-TNF between September 2002 and September 2012, 73 (0.69%) had developed TB. We described the demographic features and disease characteristics of these 73 patients and compared them to 7695 patients who were treated with anti-TNF, did not develop TB, and had complete data available. Among the 73 patients diagnosed with TB (39 men, 34 women, mean age 43.6 ± 13 yrs), the most frequent diagnoses were ankylosing spondylitis (n = 38) and rheumatoid arthritis (n = 25). More than half of the patients had extrapulmonary TB (39/73, 53%). Six patients died (8.2%). In the logistic regression model, types of anti-TNF drugs [infliximab (IFX), OR 3.4, 95% CI 1...Continue Reading

References

Mar 1, 1985·Tubercle·M HafezM R Bassiony
Mar 22, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Maria L OllerosIrene Garcia
May 6, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R S WallisD O Beenhouwer
Jan 28, 2005·The New England Journal of Medicine·UNKNOWN Wegener's Granulomatosis Etanercept Trial (WGET) Research Group
Jun 29, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Holly M Scott AlgoodJoAnne L Flynn
Dec 14, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·B DenisUNKNOWN RATIO Group
Feb 5, 2010·Lung·Denise Rossato SilvaPaulo de Tarso Roth Dalcin
Dec 21, 2010·Seminars in Arthritis and Rheumatism·Maree P WilliamsMarissa Lassere
Aug 12, 2014·Annals of Internal Medicine·Helen R StaggIbrahim Abubakar

❮ Previous
Next ❯

Citations

Oct 5, 2016·Rheumatology International·Yesim OzgulerVedat Hamuryudan
Feb 13, 2018·Current Opinion in Rheumatology·Fatma Alibaz-OnerHaner Direskeneli
Feb 7, 2018·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Nicole C Panarelli, Rhonda K Yantiss
Sep 11, 2019·Rheumatology·Yesim OzgulerMelike Melikoglu
Jan 5, 2020·Clinical Rheumatology·Natália Sarzi SartoriRafael Mendonça da Silva Chakr
Jun 22, 2017·The New England Journal of Medicine·William S DavidJohn C DeWitt
May 15, 2018·Frontiers in Cellular and Infection Microbiology·H M Adnan HameedTianyu Zhang
Dec 4, 2019·PloS One·Natália Sarzi SartoriRafael Mendonça da Silva Chakr
Jun 20, 2019·The New England Journal of Medicine·Hamed KhaliliLawrence R Zukerberg
Mar 17, 2020·Advances in Rheumatology·Gustavo Gomes ResendePercival Degrava Sampaio-Barros
Dec 11, 2020·Journal of Immunology Research·Yaxu LiuWenjie Zheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.